was used for pH adjustments of the reaction buffers.
Materials
All chemicals and reagents were purchased from commercial suppliers and used without further purification, unless otherwise noted. Neomycin B trisulfate x hydrate (VETRANAL ® 
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General procedure 1 General procedure for synthesis of activated ester 3b and 3c 2 To trifluoroacetic acid anhydride (56.4 ml, 0.47 mol) was added N-hydroxysuccinimide (20 g, 0.196 mol) at 0 °C. The reaction was allowed to war m up to r.t. over 24 hours. Then toluene (50 ml) was added and the volatile was removed in vacuo. The residue was taken up in dichloromethane (15 mL) and the remaining solvent was removed in vacuo. The resulting product, N-trifluoroacetoxysuccinimde, was used without any further purification for the next step. To a solution of carboxylic acid in 15 ml THF (15 mL) was added Ntrifluoroacetoxysuccinimide (5 g, 23.7 mmol) and pyridine (2.1 ml, 26.4 mmol) at 0 °C. The reaction mixture was allowed to warm up to r.t. over 24 h, before being quenched with water (20 mL). The aqueous phase was extracted twice with 1:1 mixture of diethyl ether and hexan (75 mL). The combinated organic phases were washed with saturated aqueous NH 4 Cl solution (100 mL), saurated aqueous NaHCO 3 solution (100 mL) and brine (100 mL), dried over MgSO 4 , filtered and concetrated to yield activated ester 3b and 3c. A 6.1 mM RNA aptamer solution (sequences: 5'-GGA CUG GGC GAG AAG UUU AGU CC-3' (apt1), 5'-CUG CAG UCC GAA AAG GGC CAG-3' (apt2) or 5'-UGU AGG GCG AAA AGU UUU ACA-3' (apt3)) (816 µL, 4.98 µmol) in 10 mM sodium phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and was afterwards kept at room te mperature for 15 min. Then a 4.8 mM solution of the aminoglycoside antibiotic (684 µL, 3.28 µmol) in 10 mM sodium phosphate buffer (pH 7.4) was added and the mixture was allowed to stand for 30 min at room temperature.
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Afterwards 30 equiv. NHS ester (98.5 µmol) dissolved in sodium phosphate buffer (1.5 mL, pH 7.4) (for activated ester 3a) or in DMF (108 µl) (for activated esters 3b and 3c) were added and the reaction mixture was allowed to react for 24 hours at room temperature. After addition of a 7 wt. % ethylamine water solution (126 µL) and further incubation for 30 min at room temperature, the crude mixture was heated to 99 °C for 10 min. To the hot solution a 53 mM aqueous solution of didodecyldimethylammonium bromide (3 mL) was added to precipitate the RNA. After incubation for 15 min at room temperature and centrifugation for 30 min at 6 °C (16.1 u/s) the supernatant was freeze-dried and dissolved in water (400 µL). Each fraction (30 µL) was purified by HPLC using a Waters Spherisorb ODS-2C 18 analytic column (water/acetone 1:0.9 containing 12.1 mM HFBA) at a flow rate of 1 ml/min at 40°C to afford the antibiotic derivatives 4a, 5 and 6. After evaporation of acetone and freeze-drying the product was 
6´´´-N-acetyl neomycin B x 5 HFBA (4a).
The title compound was prepared according to the general procedure (2.a) described above using NHS ester 3a.
Derivative 4a 
6´´´-N-
4.01 (t, J = 10 Hz, 1H, 5-H´), 3.97 -3.94 (m, 3H, 5-H´´, 5-H, 3-H´), 3.77 (dd, J = 13 Hz, J =
2´´´-N-[(4-methoxyphenyl)amino]carbonyl paromomycin x 4 HFBA (9). The title compound
was prepared according to the general procedure (2.b) described above using isocyanate 7a. 
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NMR-spectra of neomycin B and antibiotic derivatives 8a and 9 The 96-well plate was incubated overnight at 37 °C and 350 RPM. The OD 600 of all wells were measured using an E.coli ATCC 25922 culture with an OD 600 of 0.132 as reference and the MIC value was determined by taking the lowest concentration where no bacterial growth was observed.
Figure S3a

